Company profile for Inivata

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Inivata is leading the liquid biopsy revolution and transforming the lives of cancer patients. Our technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisio...
Inivata is leading the liquid biopsy revolution and transforming the lives of cancer patients. Our technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and our wider platform, which is applicable to a range of cancer types.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
7020 Kit Creek Road Suite 140 Research Triangle Park NC 27560
Telephone
Telephone
+ 844 464 8282
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/09/07/2511095/0/en/Inivata-and-Collaborators-to-Present-New-Data-to-Support-the-Application-of-RaDaR-MRD-Assay-Across-Tumor-Types-at-ESMO-Congress-2022.html

GLOBENEWSWIRE
07 Sep 2022

https://www.accesswire.com/705884/NeoGenomics-Liquid-Biopsy-Subsidiary-Inivata-Announces-New-Data-Demonstrating-Clinical-Potential-of-the-RaDaRTM-MRD-Test-in-HR-HER2-Breast-Cancer

ACCESSWIRE
20 Jun 2022

https://www.accesswire.com/700646/NeoGenomics-Liquid-Biopsy-Subsidiary-Inivata-and-Collaborators-Present-New-Data-Further-Validating-the-Application-of-its-RaDaRR-MRD-and-InVisionFirstR-Lung-Tests-at-the-2022-ASCO-Annual-Meeting

ACCESSWIRE
10 May 2022

https://www.globenewswire.com/news-release/2022/05/10/2439256/0/en/Inivata-and-Collaborators-to-Present-New-Data-Further-Validating-the-Application-of-its-RaDaR-MRD-and-InVisionFirst-Lung-Tests-at-the-2022-ASCO-Annual-Meeting.html

GLOBENEWSWIRE
10 May 2022

https://www.globenewswire.com/news-release/2022/04/11/2420241/0/en/Inivata-and-Collaborators-Publish-New-Data-on-RaDaR-MRD-Assay-at-AACR-2022.html

GLOBENEWSWIRE
11 Apr 2022

https://www.globenewswire.com/news-release/2022/03/17/2404940/0/en/Inivata-and-Collaborators-Publish-Clinical-Validation-Data-for-RaDaR-Assay-in-Non-Small-Cell-Lung-Cancer.html

GLOBENEWSWIRE
17 Mar 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty